Trial Profile

Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivoceranib (Primary) ; Epirubicin; Ethiodized oil
Indications Liver cancer
Focus Therapeutic Use

Most Recent Events

31 May 2020 Status changed to completed, according to results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
30 Apr 2018 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com